Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
Federal legislation is being considered, such as the Biosecure Act, which passed the House last year and would prohibit federal agencies and recipients of federal funds from contracting with Chinese biotech contractors like Wuxi AppTec.
- Simplified Text
-
The Biosecure Act would prohibit federal agencies from contracting with Chinese biotech contractors.
- Confidence Score
- 0.900
- Claim Maker
- Jacob Dreyer
- Context Type
- Opinion Essay
- Context Details
-
{ "date": "2025-08-17", "topic": "Biosecure Act", "company": "Wuxi AppTec", "location": "United States" } - Subject Tags
- UUID
- 9fdaec26-8093-46b7-a968-c55cde2daac2
- Vector Index
- ✗ No vector
- Created
- September 11, 2025 at 9:28 PM (2 days ago)
- Last Updated
- September 11, 2025 at 9:28 PM (2 days ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
51
claims
🔥
2 days ago
https://www.nytimes.com/2025/08/17/opinion/china-biotech.html?campaign_id=9&emc=edit_nn_20250817&instance_id=160714&nl=the-morning®i_id=122976029&segment_id=204065&user_id=b25c5730c89e0c73f75709d8f1254337
China's biotech sector is rapidly expanding, offering cheaper and faster drug manufacturing. This challenges US dominance, sparking debate on competition and collaboration.
Similar Claims (0)
Other claims identified as semantically similar to this one.
No similar claims found
This claim appears to be unique in the system.